Atossa Therapeutics (ATOS) News Today $1.20 -0.08 (-6.25%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer ResearchNovember 21 at 8:30 AM | globenewswire.comAtossa Therapeutics announces five abstracts on Z-endoxifenNovember 21 at 2:25 AM | markets.businessinsider.comAtossa Therapeutics (NASDAQ:ATOS) Lowered to Sell Rating by StockNews.comNovember 21 at 2:13 AM | americanbankingnews.comAtossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer SymposiumNovember 20 at 8:30 AM | globenewswire.comCantor Fitzgerald Brokers Lift Earnings Estimates for ATOSNovember 19 at 2:51 AM | americanbankingnews.comFY2024 EPS Estimates for ATOS Boosted by Cantor FitzgeraldAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of Atossa Therapeutics in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now aNovember 18 at 2:46 AM | marketbeat.comEquities Analysts Offer Predictions for ATOS FY2026 EarningsAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - HC Wainwright decreased their FY2026 EPS estimates for Atossa Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.32) for the year,November 15, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.00November 15, 2024 | americanbankingnews.comAtossa Therapeutics: Promising Oncology Asset and Strong Financial Position Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comAtossa Therapeutics, Inc.: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | finanznachrichten.deAtossa Therapeutics: Q3 2024 Financial Results and UpdatesNovember 13, 2024 | markets.businessinsider.comPromising Developments in Atossa Therapeutics: Advancing Endoxifen TreatmentsNovember 13, 2024 | markets.businessinsider.comAtossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Cut to Sell at StockNews.comNovember 11, 2024 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Downgraded to "Sell" Rating by StockNews.comStockNews.com cut shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.November 8, 2024 | marketbeat.comAtossa Therapeutics: Important News, But The Company Still Has A Long Way To GoNovember 8, 2024 | seekingalpha.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200 Day Moving Average - Should You Sell?Atossa Therapeutics (NASDAQ:ATOS) Stock Price Passes Above Two Hundred Day Moving Average - Here's WhyNovember 8, 2024 | marketbeat.comPositive Phase 2 Results and Rapid Efficacy Drive Buy Rating for Atossa TherapeuticsNovember 6, 2024 | markets.businessinsider.comAtossa Therapeutics appoints Claudia Lopez as VP, clinical developmentNovember 5, 2024 | markets.businessinsider.comAtossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product DevelopmentNovember 5, 2024 | globenewswire.comHR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersNovember 5, 2024 | theglobeandmail.comAtossa repots topline data from the KARISMA-Endoxifen Phase 2 studyNovember 4, 2024 | markets.businessinsider.comPromising Phase 2 Results and Strong Safety Profile Support Buy Recommendation for Atossa TherapeuticsNovember 4, 2024 | markets.businessinsider.comAtossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:November 4, 2024 | globenewswire.comBuy Rating for Atossa Therapeutics Backed by Promising Endoxifen Trial Results and Rapid Therapeutic AchievementsNovember 2, 2024 | markets.businessinsider.comAtossa Therapeutics (NASDAQ:ATOS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $6.00 price objective on shares of Atossa Therapeutics in a research report on Thursday.October 31, 2024 | marketbeat.comAtossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast CancerOctober 31, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Upgraded to "Hold" at StockNews.comStockNews.com upgraded shares of Atossa Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday.October 25, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200-Day Moving Average - What's Next?Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving Average - Time to Sell?October 23, 2024 | marketbeat.comAtossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast CancerOctober 21, 2024 | globenewswire.comAtossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual SummitOctober 14, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Stock Price Passes Above Two Hundred Day Moving Average - Here's WhyAtossa Therapeutics (NASDAQ:ATOS) Share Price Crosses Above 200-Day Moving Average - Here's WhyOctober 12, 2024 | marketbeat.comAtossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment ContinuumOctober 1, 2024 | globenewswire.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 3,160.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 411,667 shares of theSeptember 25, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200-Day Moving Average of $1.41Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving Average of $1.41September 19, 2024 | marketbeat.comAscendiant Capital Markets Boosts Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.50Ascendiant Capital Markets increased their price objective on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a research note on Wednesday.September 11, 2024 | marketbeat.comAtossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast CancerSeptember 10, 2024 | globenewswire.comAtossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.com2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%August 29, 2024 | msn.comAtossa Therapeutics Granted Additional Patent Protection for EndoxifenAugust 28, 2024 | globenewswire.comAtossa and Quantum Leap dose first subject in breast cancer therapy trialAugust 22, 2024 | finance.yahoo.comAtossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerAugust 21, 2024 | globenewswire.comAtossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerAugust 21, 2024 | globenewswire.comAtossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public RelationsAugust 20, 2024 | globenewswire.comFY2024 Earnings Estimate for Atossa Therapeutics, Inc. (NASDAQ:ATOS) Issued By Cantor FitzgeraldAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Atossa Therapeutics in a report released on Tuesday, August 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($0.22) per share for tAugust 15, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPSAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01.August 13, 2024 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Cut to "Sell" at StockNews.comStockNews.com downgraded Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Monday.August 12, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Atossa Therapeutics (NASDAQ:ATOS)HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Atossa Therapeutics in a research report on Monday.August 12, 2024 | marketbeat.comAtossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 12, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200 Day Moving Average of $1.29Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.29July 25, 2024 | marketbeat.com Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide ATOS Media Mentions By Week ATOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼0.510.46▲Average Medical News Sentiment ATOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼142▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EYEG News PHAT News EXAI News ORIC News STOK News OCS News ANAB News TECX News TRML News IMNM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATOS Stock Alerts